Zimura® for Dry AMD Continues to Show Positive Results in Trials

In January 2017, Ophthotech Corporation (now known as Iveric), announced that the first patient had been dosed in a Phase 2/3 clinical study of Zimura® (avacincaptad pegol sodium) for treatment of advanced dry macular degeneration (aka geographic atrophy). Zimura® inhibits complement factor C5, which is believed to be involved in the development of AMD.

On Oct. 28, 2019, Iveric confirmed that Zimura® has met its prespecified primary endpoint in reducing the rate of geographic atrophy growth in patients in a randomized, controlled Phase 2b clinical trial. Patients will continue to be treated and followed through month 18 in order to collect additional data.

To read about this and other treatments under study for dry MD, see A guide to Research in Dry Macular Degeneration.

Source: Press Release